Article
Medicine, General & Internal
Yuanyuan Zhao, Yunpeng Yang, Fangfang Gao, Changlu Hu, Diansheng Zhong, Miaozhen Lu, Zhiping Yuan, Jianqing Zhao, Jidong Miao, Yan Li, Jie Zhu, Chunbin Wang, Jianjun Han, Yanqiu Zhao, Yan Huang, Li Zhang
Summary: This study evaluated the efficacy of olanzapine combined with triple antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving multiday chemotherapy. The results showed that olanzapine (5 mg) combined with fosaprepitant, ondansetron, and dexamethasone was more effective than triple antiemetic therapy alone. The four-drug combination should be recommended as the best antiemetic regimen for patients receiving multiday cisplatin-based chemotherapy.
Article
Pharmacology & Pharmacy
Yun An, Zewei Zhang, Min Gu, Juan Zhao, Caihong Jiang, Lanzhen Zhao, Ying Jiang, Hui Li, Guang Liu, Gaowa Jin, Quanfu Li
Summary: The effectiveness and safety of 5 mg olanzapine in preventing vomiting and nausea caused by carboplatin chemotherapy were investigated in this study. The results showed that the olanzapine regimen significantly improved the total control rates and delayed the first vomiting time compared to the standard group. Additionally, the olanzapine regimen had a positive impact on the quality of life for patients.
CURRENT PHARMACEUTICAL DESIGN
(2023)
Article
Oncology
Nurul Suhaida Badarudin, Noraida Mohamed Shah, Kamarun Neasa Begam Mohd Kassim, Fuad Ismail, Farida Islahudin, Nurul Ain Mohd Tahir, Suhana Yusak
Summary: This study investigated the incidence of chemotherapy-induced nausea vomiting (CINV) and the prescribing pattern of CINV prophylaxis in patients receiving highly and moderately emetogenic chemotherapy. The study found that the incidence of CINV was high per patient but relatively low per cycle. Most patients were prescribed with dual regimen antiemetic prophylaxis. The study suggests that there is suboptimal use of recommended agents for CINV and further improvements in CINV management are needed.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Oncology
Ronald Chow, Leonard Chiu, Jorn Herrstedt, Matti Aapro, Michael Lock, Carlo DeAngelis, Rudolph M. Navari
Summary: The study finds that olanzapine-containing regimens are both cheaper and more effective in preventing CINV in HEC patients compared to non-olanzapine regimens. Future CINV trial resources should focus on exploring newer antiemetics and comparing them to olanzapine-containing regimens. Further analysis should consider using nationally representative data to examine medication costs by payer type.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Oncology
Rudolph M. Navari, Kathryn J. Ruddy, Thomas W. LeBlanc, Ryan Nipp, Rebecca Clark-Snow, Lee Schwartzberg, Gary Binder, William L. Bailey, Ravi Potluri, Luke M. Schmerold, Eros Papademetriou, Eric J. Roeland
Summary: This study aimed to analyze the need for acute care after highly emetogenic chemotherapy (HEC) regimens, finding that patients experienced high levels of avoidable acute care, with nonadherence to antiemesis guidelines being the main contributing factor.
Article
Oncology
Yu Sun, Yuzhu Zheng, Xiaoyun Yang, Ke Xie, Chi Du, Lang He, Yan Gui, Jiangping Fu, Changlin Li, Huiling Zhang, Li Zhu, Jun Bie, Yi Sun, Yu Fu, Yangang Zhou, Feng Shou, Yan Wang, Jiang Zhu
Summary: This study aimed to investigate the occurrences of nausea and vomiting in cancer patients undergoing chemotherapy, finding a high incidence of CINV and the possibility of occurrence beyond the risk period. The results suggest that standardized use of antiemetic medications may be key to improving the prevention and control of CINV.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Oncology
Alexandra M. Walsh, Jennifer Hess, Melissa Rees, Cynthia Wetmore, Vinay Vadiya
Summary: Chemotherapy can cause nausea and vomiting, affecting patients' quality of life. A new dashboard was created to help healthcare providers manage antiemetic regimens more effectively for pediatric oncology patients.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Oncology
Matti Aapro, Zoe Caprariu, Petio Chilingirov, Marika Chrapava, Razvan-Ovidiu Curca, Laurentia Gales, Alexandru C. Grigorescu, Joanna Huszno, Bara Karlinova, Renata Kellnerova, Miroslava Malejcikova, Mihai Marinca, Edgar Petru, Adam Pluzanski, Petra Pokorna, Zuzana Pribulova, Maryna Rubach, Gunther G. Steger, Petra Tesarova, Lubica Valekova, Nicolay Yordanov, Anna Walaszkowska-Czyz
Summary: This study evaluated the application of evidence-based antiemetic guidelines in the prevention of chemotherapy-induced nausea and vomiting. The study found inconsistencies between clinical practice and guideline-recommended treatment. Patients receiving guideline-consistent prophylaxis had significantly higher complete response rates and less impact on daily living compared to patients receiving guideline-inconsistent treatment.
EUROPEAN JOURNAL OF CANCER
(2022)
Review
Medicine, General & Internal
Anabella Karla Barusic
Summary: This review evaluates the use of olanzapine in pediatric chemotherapy-induced nausea and vomiting (CINV) and suggests that adding olanzapine to antiemetic regimens may be beneficial. However, further research is needed to establish its efficacy and safety in pediatric CINV control.
Article
Medicine, General & Internal
Yi Cheng, Zehua Wu, Lishuo Shi, Cailu Shen, Jianwei Zhang, Huabin Hu, Weiwei Li, Yue Cai, Xiaoyu Xie, Jiayu Ling, Qin Zheng, Yanhong Deng
Summary: This study evaluated the efficacy of aprepitant combined with palonosetron in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderate-emetogenic chemotherapy (MEC). The results showed that aprepitant was superior to dexamethasone in terms of achieving a complete response in preventing CINV, with fewer reported side effects in the aprepitant group.
Review
Nutrition & Dietetics
Devanshi Gala, Hattie H. Wright, Bekhinkosi Zigori, Skye Marshall, Megan Crichton
Summary: The study suggests that CINV-specific nutrition education and support from health professionals can improve CINV. Non-restrictive dietary patterns, particularly those including adequate energy and macronutrient intakes, ginger, and Mediterranean diet concepts, may benefit CINV.
CLINICAL NUTRITION
(2022)
Article
Oncology
Mashari Jemaan Alzahrani, George Dranitsaris, Marta Sienkiewicz, Lisa Vandermeer, Mark Clemons
Summary: This study assessed the predictive ability of a personalized risk model in stratifying patients' risk for chemotherapy-induced nausea and vomiting (CINV). The PRM successfully identified patients at higher risk of significant nausea but did not show significant differences in predicting other CINV endpoints.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Oncology
Chizuru Sakai, Mototsugu Shimokawa, Hirotoshi Iihara, Yukiyoshi Fujita, Shinnosuke Ikemura, Chiemi Hirose, Mie Kotake, Norihiko Funaguchi, Takenobu Gomyo, Hisao Imai, Jun Hakamata, Daizo Kaito, Koichi Minato, Takahiro Arai, Hitoshi Kawazoe, Akio Suzuki, Yasushi Ohno, Hiroyuki Okura
Summary: The study demonstrated that prophylactic antiemetic therapy with a low dose of 5 mg olanzapine in combination with granisetron and dexamethasone showed durable efficacy and acceptable safety profile in patients with thoracic malignancies.
Article
Pharmacology & Pharmacy
Jouko Levijoki, Lasse Saloranta, Johanna Tuunainen, Janne Kaskinoro, Sari Pappinen, Sandra Nourry, Anne-Marie Betat, Anne Maurin, Maarit Pakarinen, Sari Hakkinen, Johanna Tervapuro, Hertta Pihlasvaara, Christophe Drieu La Rochelle, Heikki Joensuu
Summary: Ocular administration of palonosetron as eye drops can effectively prevent and treat nausea and vomiting. This method provides a quick and convenient way to deliver the medication when intravenous administration is not possible.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(2023)
Article
Medicine, General & Internal
De-Shen Wang, Ming-Tao Hu, Zhi-Qiang Wang, Chao Ren, Miao-Zhen Qiu, Hui-Yan Luo, Ying Jin, William Pat Fong, Shu-bin Wang, Jie-wen Peng, Qing-feng Zou, Qiong Tan, Feng-Hua Wang, Yu-Hong Li
Summary: This study aimed to evaluate the efficacy and safety of adding aprepitant to palonosetron and dexamethasone for women with gastrointestinal cancer undergoing FOLFIRI or FOLFOX chemotherapy regimens. The results showed a significantly higher CR rate in the aprepitant group compared to the control group, with similar safety profiles.
Article
Surgery
Grace Hsu, Tracy M. Sparkes, Brent N. Reed, Stormi E. Gale, Brian E. Crossley, Bharath R. Ravichandran
Summary: This study found that pretransplant cardiovascular risk was not strongly associated with graft outcomes. In patients without prior cardiovascular disease, rates of graft failure and major adverse cardiovascular events were similar across different risk groups. In patients with prior disease, some risks were increased for adverse events, but after adjusting for age, gender, and race, the association became insignificant for major adverse cardiovascular events and heart failure.
PROGRESS IN TRANSPLANTATION
(2021)
Article
Pharmacology & Pharmacy
Grace Hsu, Jeffrey P. Gonzales, Hyunuk Seung, Mojdeh S. Heavner, Wisna Jean, Nirav G. Shah
JOURNAL OF PHARMACY TECHNOLOGY
(2020)
Meeting Abstract
Critical Care Medicine
Grace Hsu, Jeffrey Gonzales, Mojdeh Heavner, Wisna Jean
CRITICAL CARE MEDICINE
(2019)